Q-omics provides the consensus-scored ST7-AS2 profile across patient tissues and cancer cell-line models. ST7-AS2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, ST7-AS2 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ST7-AS2 RNA expression shows 10,379 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CHOL, KIRP, and UVM as cancer lineages where ST7-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST7-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST7-AS2 survival associations across molecular data types. ST7-AS2 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST7-AS2 RNA expression–survival associations across cancer types. High ST7-AS2 expression shows unfavorable associations in LGG, but favorable associations in CHOL, READ, LIHC, OV and UCS. The CHOL Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify CHOL as the clearest survival context for ST7-AS2 RNA expression.
This table summarizes ST7-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ST7-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST7-AS2 shows lower tumor expression in KIRP, KICH, KIRC, LUSC and THCA and higher tumor expression in HNSC. The KIRP box plot shows higher ST7-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p < 0.001).
This table shows molecular features associated with ST7-AS2 in patient tissues and cancer cell lines. In patient samples, ST7-AS2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
